Rajput SN, Naeem BK, Ali A, Salim A, Khan I. Expansion of human umbilical cord derived mesenchymal stem cells in regenerative medicine. World J Stem Cells 2024; 16(4): 410-433 [PMID: 38690517 DOI: 10.4252/wjsc.v16.i4.410]
Corresponding Author of This Article
Irfan Khan, PhD, Assistant Professor, Center for Regenerative Medicine and Stem Cells Research, and Department of Ophthalmology and Visual Sciences, The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Sindh, Pakistan. irfankhan.bangash@aku.edu
Research Domain of This Article
Cell Biology
Article-Type of This Article
Basic Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Shafiqa Naeem Rajput, Asmat Salim, Irfan Khan, Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi 75270, Sindh, Pakistan
Bushra Kiran Naeem, Surgical Unit 4, Dr. Ruth KM Pfau Civil Hospital, Karachi 74400, Pakistan
Anwar Ali, Department of Physiology, University of Karachi, Karachi 75270, Pakistan
Irfan Khan, Center for Regenerative Medicine and Stem Cells Research, and Department of Ophthalmology and Visual Sciences, The Aga Khan University, Karachi 74800, Sindh, Pakistan
Author contributions: Rajput SN performed experiments and wrote the original manuscript; Naeem BK helped in data evaluation and writing; Ali A contributed to the experimentation and writing; Salim A reviewed the manuscript; Salim A and Khan I evaluated and analyzed the data; Khan I conceived and designed the studies and finalized the manuscript.
Institutional review board statement: The ethical approval for the present study was obtained from the Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi (IEC document No. 40/2020/QD-VINMEC) in accordance with the Helsinki Declaration.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: All the data is presented in the manuscript. The raw data will be provided upon request.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Irfan Khan, PhD, Assistant Professor, Center for Regenerative Medicine and Stem Cells Research, and Department of Ophthalmology and Visual Sciences, The Aga Khan University, Stadium Road, P.O. Box 3500, Karachi 74800, Sindh, Pakistan. irfankhan.bangash@aku.edu
Received: November 30, 2023 Peer-review started: November 30, 2023 First decision: January 15, 2024 Revised: February 1, 2024 Accepted: March 18, 2024 Article in press: March 18, 2024 Published online: April 26, 2024 Processing time: 146 Days and 16.4 Hours
Core Tip
Core Tip: Therapeutic transplantation of mesenchymal stem cells (MSCs) requires one to four million cells/kg of body weight. Ex vivo expansion of stable MSCs at higher passage numbers limits their clinical applications due to senescence, variation in genetic stability and short life span. This study results in the development of a cutting-edge protocol for scaling the stem cell population ex vivo in less time. It rapidly increases the cell number in vitro to fulfill in vivo therapeutic cell doses. This method might decrease immune rejection. Since these MSCs were isolated from the same recultured human umbilical cord, they have persistent MSC stemness and may decrease tissue vs graft rejection due to the less rigorous HLA screening required in allogenic transplantation, which could make it more cost-effective. More studies that are exploratory should be carried out to further elucidate the mechanism via preclinical and clinical applications.
